NICE does not recommend Cotellic (cobimetinib )plus Zelboraf (vemurafenib) as a cost effective combination for metastatic melanoma.- Roche

NICE (The National Institute for Health and Care Excellence) has in draft guidance decided that cobimetinib ( Cotellic from Roche) in combination with vemurafenib (Zelboraf) is not recommended within its marketing authorisation for treatment of unresectable or metastatic melanoma in adults with a BRAF V600 mutation. NICE advised that the addition of cobimetinib to Zelboraf does increase overall survival by 4.9 months but that does not justify its cost. A list price of �4,275.67 for 63 tablets brings the price per quality-adjusted life year, or QALY, to more than �100,000, which is �substantially above the range usually considered to be a cost-effective use of NHS resources".